Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study

Raymond Javan Chan¹, Reegan Knowles¹, Fredrick D Ashbury², Joanne Bowen³, Alexandre Chan⁴, Melissa Chin⁵, Ian Olver⁶, Carolyn Taylor⁷, Stacey Tinianov⁸, Paola Alberti^{9

10}, Paolo Bossi^{11

12}, Norman Brito-Dellan¹³, Tim Cooksley¹⁴, Gregory Brian Crawford^{6

15}, Niharika Dixit^{16

17}, Margaret I Fitch¹⁸, Jason L Freedman^{19

20}, Pamela K Ginex²¹, Nicolas H Hart^{1

22}, Daniel L Hertz²³, Michael Jefford^{24

25}, Bogda Koczwara^{26

27}, Tateaki Naito²⁸, Andrea Dahlman Orsey^{29

30}, Christina H Ruhlmann³¹, Nikolaos Tsoukalas³², Corina van den Hurk³³, Ysabella Van Sebille³⁴, Hannah Rose Wardill^{3

35}, Florian Scotte³⁶, Maryam Lustberg³⁷; Multinational Association of Supportive Care in Cancer (MASCC) Study Group Chairs

Affiliations

¹ Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Flinders Drive, Bedford Park, South Australia, Australia.
² Department of Oncology, University of Calgary, Alberta, Canada.
³ School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.
⁴ Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, University of California, 802 W Peltason Dr, Irvine, CA, United States.
⁵ Multinational Association of Supportive Care in Cancer, 16 Industrial Parkway South Unit 412, Aurora, ON L4G 0R1, Canada.
⁶ School of Psychology, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.
⁷ Global Focus on Cancer, 26 Hemlock Rd Suite 101, South Salem, NY 10590, United States.
⁸ Advocates for Collaborative Education, Santa Cruz, CA, United States.
⁹ School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
¹⁰ Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
¹¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan 20072, Italy.
¹² IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan 20089, Italy.
¹³ The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, United States.
¹⁴ The Christie, Wilmslow Rd, Manchester, United Kingdom.
¹⁵ Northern Adelaide Local Health Network, South Australia, Australia.
¹⁶ Division of Hematology/Oncology, University of California, San Francisco, CA, United States.
¹⁷ Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA, United States.
¹⁸ Bloomberg Faculty of Nursing, University of Toronto, 155 College Str, Suite 130, Toronto, Ontario, Canada.
¹⁹ Division of Oncology, Children's Hospital of Philadelphia, 3400 Civic Center Blvd, Philadelphia, PA, United States.
²⁰ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, United States.
²¹ State University of New York, Nicolls Rd, Stony Brook, NY, United States.
²² Human Performance Research Centre, INSIGHT Research Institute, Faculty of Health, University of Technology Sydney (UTS), 235 Jones Str, Ultimo, Sydney, New South Wales, Australia.
²³ Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church Str, Ann Arbor, MI, United States.
²⁴ Department of Health Services Research, Peter MacCallum Cancer Centre, 305 Grattan Str, Melbourne, Victoria, Australia.
²⁵ Sir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Str, Melbourne, Victoria, Australia.
²⁶ Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, Australia.
²⁷ Flinders University, Flinders Health and Medical Research Institute, Flinders Drive, Bedford Park, South Australia, Australia.
²⁸ Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Japan.
²⁹ Center for Cancer and Blood Disorders, Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT 06106, United States.
³⁰ Department of Pediatrics, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, United States.
³¹ Department of Oncology, Odense University Hospital, Denmark - Department of Clinical Research, University of Southern Denmark, Denmark.
³² Oncology Department, 401 General Military Hospital of Athens, Greece.
³³ R&D Department, Netherlands Comprehensive Cancer Organization (IKNL), Rijnkade 5, Utrecht 3511 LC, the Netherlands.
³⁴ University of South Australia, Level 4, Catherine Helen Spence Building, City West, Adelaide, South Australia, Australia.
³⁵ The Supportive Oncology Research Group, Precision Cancer Medicine Theme, The South Australian Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
³⁶ Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif CEDEX, Paris, France.
³⁷ Smilow Cancer Hospital at Yale, 35 Park Street, Fl 1st, Suite A, New Haven, CT 06511, United States.

PMID: 39309723
PMCID: PMC11415959
DOI: 10.1016/j.eclinm.2024.102825

Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study

Raymond Javan Chan et al. EClinicalMedicine. 2024.

. 2024 Sep 11:76:102825.

doi: 10.1016/j.eclinm.2024.102825. eCollection 2024 Oct.

Authors

Affiliations

¹ Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Flinders Drive, Bedford Park, South Australia, Australia.
² Department of Oncology, University of Calgary, Alberta, Canada.
³ School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.
⁴ Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, University of California, 802 W Peltason Dr, Irvine, CA, United States.
⁵ Multinational Association of Supportive Care in Cancer, 16 Industrial Parkway South Unit 412, Aurora, ON L4G 0R1, Canada.
⁶ School of Psychology, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.
⁷ Global Focus on Cancer, 26 Hemlock Rd Suite 101, South Salem, NY 10590, United States.
⁸ Advocates for Collaborative Education, Santa Cruz, CA, United States.
⁹ School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
¹⁰ Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
¹¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan 20072, Italy.
¹² IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan 20089, Italy.
¹³ The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, United States.
¹⁴ The Christie, Wilmslow Rd, Manchester, United Kingdom.
¹⁵ Northern Adelaide Local Health Network, South Australia, Australia.
¹⁶ Division of Hematology/Oncology, University of California, San Francisco, CA, United States.
¹⁷ Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA, United States.
¹⁸ Bloomberg Faculty of Nursing, University of Toronto, 155 College Str, Suite 130, Toronto, Ontario, Canada.
¹⁹ Division of Oncology, Children's Hospital of Philadelphia, 3400 Civic Center Blvd, Philadelphia, PA, United States.
²⁰ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, United States.
²¹ State University of New York, Nicolls Rd, Stony Brook, NY, United States.
²² Human Performance Research Centre, INSIGHT Research Institute, Faculty of Health, University of Technology Sydney (UTS), 235 Jones Str, Ultimo, Sydney, New South Wales, Australia.
²³ Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church Str, Ann Arbor, MI, United States.
²⁴ Department of Health Services Research, Peter MacCallum Cancer Centre, 305 Grattan Str, Melbourne, Victoria, Australia.
²⁵ Sir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Str, Melbourne, Victoria, Australia.
²⁶ Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, Australia.
²⁷ Flinders University, Flinders Health and Medical Research Institute, Flinders Drive, Bedford Park, South Australia, Australia.
²⁸ Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Japan.
²⁹ Center for Cancer and Blood Disorders, Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT 06106, United States.
³⁰ Department of Pediatrics, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, United States.
³¹ Department of Oncology, Odense University Hospital, Denmark - Department of Clinical Research, University of Southern Denmark, Denmark.
³² Oncology Department, 401 General Military Hospital of Athens, Greece.
³³ R&D Department, Netherlands Comprehensive Cancer Organization (IKNL), Rijnkade 5, Utrecht 3511 LC, the Netherlands.
³⁴ University of South Australia, Level 4, Catherine Helen Spence Building, City West, Adelaide, South Australia, Australia.
³⁵ The Supportive Oncology Research Group, Precision Cancer Medicine Theme, The South Australian Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
³⁶ Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif CEDEX, Paris, France.
³⁷ Smilow Cancer Hospital at Yale, 35 Park Street, Fl 1st, Suite A, New Haven, CT 06511, United States.

PMID: 39309723
PMCID: PMC11415959
DOI: 10.1016/j.eclinm.2024.102825

Abstract

Background: Supportive care to ensure optimal quality of life is an essential component of cancer care and symptom control across the lifespan. Ongoing advances in cancer treatment, increasing toxicity from many novel treatment regimes, and variations in access to care and cancer outcomes across the globe and resource settings present significant challenges for supportive care delivery. To date, no overarching framework has been developed to guide supportive care development worldwide. As an initial step of the Multinational Association of Supportive Care in Cancer (MASCC) Supportive Care 2030 Movement, we developed a targeted, unifying set of ambition statements to envision the future of supportive cancer care.

Methods: From September 2022 until June 2023, we used a modified Delphi methodology to develop and attain consensus about ambition statements related to supportive cancer care. Leaders of MASCC Study Groups were invited to participate in an Expert Panel for the first two Delphi rounds (and a preliminary round to suggest potential ambition statements). Patient Advocates then examined and provided input regarding the ambition statements.

Findings: Twenty-seven Expert Panelists and 11 Patient Advocates participated. Consensus was attained on 13 ambition statements, with two sub-statements. The ambition statements addressed global standards for guideline development and implementation, coordinated and individualized care, dedicated supportive oncology services, self-management, needs for screening and actions, patient education, behavioral support, financial impact minimization, comprehensive survivorship care, and timely palliative care, reflecting collaboration, coordination and team-based approach across all levels.

Interpretation: This study is the first to develop shared ambitions for the future of supportive cancer care on a global level. These ambition statements can facilitate a coordinated, resource-stratified, and person-centered approach and inform research, education, clinical services, and policy efforts.

Funding: This project received funding support from Prof Raymond Chan's NHMRC Investigator Grant (APP1194051).

Keywords: Optimal care; Palliative care; Supportive care; Supportive oncology; Toxicity.

PubMed Disclaimer

Conflict of interest statement

All authors declare their leadership roles within the Multinational Association for Supportive Care in Cancer. The individual authors also reported their respective conflicts of interest, however are not judged to be directly relevant to the conduct of this study. FA reported reimbursement from VieCure for travel-related expenses to attend ASCO 2024 and MASCC 2024; US Patent No. 11, 798,689 B2: AI decision-support platform to generate patient-specific health plans based on unique patient circumstances; Clinical Advisory Committee Chair—VieCure; Stock—VieCure Oncology Decision Support Platform. IO reported receiving reimbursement from MASCC to travel to 2022 and 2023 MASCC Annual Scientific Meetings; and Chair of SAX Institute Board. CT reported Leadership or fiduciary roles: Executive Director, Global Focus on Cancer; Advisory Board, Asia Pacific Oncology Alliance; Steering Committee, WHO Symposium on Meaningful Engagement; Editorial Board, Cancer Survivorship Research & Care Journal. PB reported receiving consulting fees from Angelini, Nestle, Nutricia and Molteni; and participation on Angelini Advisory Board/Data Safety Monitoring Board. TN reported receiving research funding from Otsuka Pharmaceutical CO, Ltd, and Kracie Ltd; and lecture fee for ONO Pharmaceutical CO Ltd. ADO reported Pfizer stock ownership. HW reported she is the recipient of a Hospital Research Foundation Research Fellowship. FS reported payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Sanofi, Roche, MSD, Prostrakan, Leo pharma, Janssen, Pfizer, Amgen, Pierre Fabre Oncologie, Pharmanovia, Vifor Pharma, GSK, Viatris, Helsinn, Gilead, and Daichy Sankyo. PA reported receiving grant (250.000 euros) from Cariplo Foundation; consulting fees from GHD Healthcare, Oncosultions, LLC, and Techspert. IO LTD.

Figures

**Fig. 1**
Summary of the development of the final list of ambition statements. AS, Ambition statements; SS, Sub-statements.

**Fig. 2**
World map illustrating residence of Expert Panel and Patient Advocate study participants.

**Fig. 3**
Supportive Care in Cancer 2030 Ambition Statements (with preamble) final list. MASCC, Multinational association supportive care in cancer; PROM, Patient reported outcome measures; PREM, Patient reported experience measures.

See this image and copyright information in PMC

References

1. Scotté F., Taylor A., Davies A. Supportive care: the “keystone” of modern oncology practice. Cancers. 2023;15(15):3860. - PMC - PubMed
1. Lustberg M.B., Kuderer N.M., Desai A., Bergerot C., Lyman G.H. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527–542. - PMC - PubMed
1. Fitch M.I. Supportive care framework. Can Oncol Nurs J. 2008;18(1):6–24. - PubMed
1. Fitch M. Supportive care for cancer patients. Hosp Q. 2000;3(4):39–46. - PubMed
1. Harrison J.D., Young J.M., Price M.A., Butow P.N., Solomon M.J. What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer. 2009;17(8):1117–1128. - PubMed

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study

Affiliations

Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials